Overview
VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas. It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy.
Development
- Ongoing multi-center Phase 1/2a dose-escalation/expansion trial (NCT05655312) evaluating [212Pb]VMT01 as monotherapy and in combination with nivolumab in patients with unresectable or metastatic MC1R-positive melanoma, currently recruiting across the US
- First patient dosed in combination arm (with nivolumab) in March 2025; dose finding progressing at 3.0 mCi for both monotherapy and combination, with no dose-limiting toxicities reported as of September 2025
- Preclinical data demonstrate synergistic effects with immune checkpoint inhibitors; combination cohort actively enrolling
- Phase 1 imaging study at Mayo Clinic supports patient selection using [203Pb]VMT01 and [68Ga]VMT02, confirming feasibility for MC1R targeting
- Fast Track Designation granted by FDA (September 2024) for diagnosis and treatment of MC1R-positive melanoma
- Clinical updates on safety, dosimetry, and efficacy expected mid to late 2026, with potential for expanded enrollment and regulatory discussions
